U.S. Patent 7,615,545: Scope, Claims, Expiration, and Generic Entry Risk for Seasonique

U.S. Patent No. 7,615,545 protected an extended-cycle oral contraceptive regimen associated with Seasonique: 84 consecutive days of ethinyl estradiol plus levonorgestrel followed by seven days of low-dose ethinyl estradiol without progestin. The patent also covered broader 81-to-89-day regimens, transdermal administration, monophasic dosing, and selected antidepressant co-administration.

The patent issued on November 10, 2009, from a family claiming priority to December 2000. Its Orange Book term expired in December 2021. The patent therefore no longer creates an enforceable U.S. patent barrier to generic or competing extended-cycle contraceptive products, although its claims remain important for understanding the historical exclusivity strategy around Seasonique.

What drug and regimen did U.S. Patent 7,615,545 protect?

The patent protected a method of contraception using:

Phase	Duration	Estrogen	Progestin
Active phase	81-89 consecutive days	Equivalent to 10-50 μg ethinyl estradiol daily	50-150 μg levonorgestrel daily
Estrogen-only phase	2-8 consecutive days	Equivalent to 5-10 μg ethinyl estradiol daily	None
Narrow commercial embodiment	84 days	30 μg ethinyl estradiol daily	150 μg levonorgestrel daily
Final phase in narrow embodiment	7 days	10 μg ethinyl estradiol daily	None

The commercial regimen most closely reflected by claims 22-24 is:

84 daily doses containing 30 μg ethinyl estradiol and 150 μg levonorgestrel;
followed by seven daily doses containing 10 μg ethinyl estradiol;
oral, monophasic administration;
no progestin during the seven-day estrogen-only interval.

That regimen corresponds to the extended-cycle design used in Seasonique and related products.

What are the independent claims of U.S. Patent 7,615,545?

The patent has five principal independent claims: claims 1, 18, 19, 20, and 22.

Claim 1: Broad regimen claim

Claim 1 covers a contraceptive method requiring all of the following:

A female in need of contraception.
A combined estrogen-progestin dosage for 81-89 consecutive days.
A subsequent estrogen-only dosage for 2-8 consecutive days.
Estrogen during the combined phase equivalent to 10-50 μg of ethinyl estradiol per day.
Estrogen during the final phase equivalent to 5-10 μg of ethinyl estradiol per day.
Levonorgestrel at 50-150 μg per day during the combined phase.

The claim is broad in duration, estrogen identity, route of administration, and formulation. It does not require oral administration, monophasic dosing, exactly 84 active days, or exactly seven estrogen-only days.

The phrase “equivalent to” permits estrogen compounds other than ethinyl estradiol if the administered dose produces an equivalent estrogenic amount. Claim scope therefore extends beyond a literal formulation containing ethinyl estradiol, subject to claim construction and proof of equivalence.

Claims 18 and 19: Oral monophasic embodiments

Claims 18 and 19 narrow the regimen to:

oral administration;
monophasic dosing;
84 consecutive days of estrogen plus levonorgestrel;
seven consecutive days of estrogen without progestin;
10-50 μg or 10-30 μg of ethinyl estradiol during the active phase;
10 μg of ethinyl estradiol during the final phase;
50-150 μg of levonorgestrel during the active phase.

Claim 19 is narrower than claim 18 because the active-phase estrogen range is limited to 10-30 μg.

Claims 20 and 22: Estrogen without progestin

Claim 20 is directed to the same 84/7 oral monophasic regimen but expressly requires estrogen without progestin during the seven-day final phase.

Claim 22 narrows the active phase to the specific commercial strength of:

30 μg ethinyl estradiol;
150 μg levonorgestrel;
84 consecutive days;

followed by:

10 μg ethinyl estradiol;
seven consecutive days;
no progestin.

Claims 22-24 provide the most product-specific protection in the patent. Claim 23 requires the final dosage to contain estrogen and one or more pharmaceutically acceptable excipients. Claim 24 uses the “consisting essentially of” formulation, which generally permits excipients and other components that do not materially affect the claimed contraceptive regimen.

How do the dependent claims expand the patent scope?

The dependent claims create fallback positions around the principal regimen.

Claims	Added limitation	Commercial significance
2	Active-phase estrogen equivalent to 10-30 μg ethinyl estradiol	Covers lower-dose extended regimens
3	30 μg ethinyl estradiol	Matches the principal Seasonique strength
4	10 μg ethinyl estradiol in the final phase	Matches the low-dose estrogen interval
5	At least 84 active days	Protects the standard extended-cycle schedule
6-7	Final phase of 5-8 days, or at least 7 days	Captures the usual seven-day interval
8	Exactly 84 active days and seven final days	Directly targets the standard 84/7 regimen
9	Estrogen is ethinyl estradiol	Removes broader estrogen alternatives
10-14	Antidepressant administration, including fluoxetine	Covers symptom-management variations
15	Oral administration	Targets tablets or oral dosage forms
16	Transdermal administration	Extends the method to patches or other transdermal systems
17	Monophasic administration	Targets uniform daily active-phase doses

The antidepressant claims are ancillary rather than central to Seasonique’s principal product protection. Claim 12 specifies fluoxetine hydrochloride at an amount equivalent to approximately 5-120 mg per day during the estrogen-only interval. Claims 13 and 14 cover one-time administration and fluoxetine hydrochloride, respectively.

What formulations are protected by U.S. Patent 7,615,545?

The patent is primarily a regimen patent, not a conventional composition-of-matter patent.

It does not claim a new molecular entity, a novel salt, a proprietary excipient system, or a specific tablet manufacturing process. Its protection arises from the sequence, duration, dose, and route of administration.

Oral tablets

The strongest product-facing embodiments are oral monophasic tablets containing:

30 μg ethinyl estradiol;
150 μg levonorgestrel;
administered for 84 days;

followed by tablets containing:

10 μg ethinyl estradiol;
no progestin;
administered for seven days.

A generic product with the same labeled regimen would have historically presented the clearest risk under claims 18-24.

Transdermal products

Claim 16 extends the broad method to transdermal administration. The claim does not require a specific patch, reservoir, adhesive, release profile, or delivery technology. Its practical value would depend on whether a transdermal product delivered estrogen and levonorgestrel in the claimed daily amounts and followed the claimed 84/7 or related schedule.

Monophasic products

Claim 17 and the narrower independent claims cover monophasic administration. A monophasic regimen generally provides the same daily active dose throughout the relevant phase. A multiphasic product could avoid the monophasic limitation in claims 17-24, but might still implicate claim 1 if it otherwise met the broader dose and duration limitations.

When did U.S. Patent 7,615,545 expire?

The patent expired in December 2021. The Orange Book term associated with the patent was December 22, 2021. The patent is no longer an enforceable U.S. exclusionary right against new generic launches.

The patent’s term was governed by the 20-year patent term measured from the relevant nonprovisional filing date, subject to any applicable patent-term adjustment. The patent’s November 2009 issuance date did not reset the term.

Regulatory exclusivity

Seasonique was approved by the FDA under NDA 021544 on September 25, 2006. Its regulatory exclusivity was separate from patent protection and expired substantially earlier than the patent term.

Seasonique did not receive the type of five-year new chemical entity exclusivity associated with a newly approved active pharmaceutical ingredient because ethinyl estradiol and levonorgestrel were established active ingredients. Any three-year clinical-investigation exclusivity associated with the approval would not have extended into the period when the patent remained the principal commercial barrier. [2]

What was the Orange Book status of U.S. Patent 7,615,545?

The patent was listed in the FDA Orange Book for Seasonique-related approval coverage. Its listing functioned as a notice to ANDA applicants that the reference product was subject to a patent directed to the contraceptive regimen.

The patent was a method-of-use listing rather than a composition-of-matter patent. For an ANDA applicant, the principal regulatory route to challenge the patent was a Paragraph IV certification asserting that the patent was invalid, unenforceable, or would not be infringed.

After expiration, the listing no longer supports a continuing Paragraph IV-based entry delay. A generic applicant can rely on an ordinary patent-expired certification for the expired patent, subject to other listed patents and regulatory requirements.

Which companies challenged or competed with the Seasonique patent position?

The commercial landscape involved the original sponsor, its corporate successor, and generic manufacturers.

Company	Role	Relevant product or position
Duramed Pharmaceuticals	Original developer and sponsor affiliate	Developed the extended-cycle contraceptive platform
Barr Pharmaceuticals	Parent company of Duramed before acquisition	Commercialized Seasonique
Teva Pharmaceutical Industries	Acquired Barr in 2008	Inherited the Seasonique business and related IP
Watson Pharmaceuticals	Generic manufacturer, later part of Actavis/Allergan	Developed or marketed generic extended-cycle contraceptive products
Amneal and other generic manufacturers	Later generic competition	Potential competition after patent and exclusivity expiration

Products such as Amethia and Camrese competed in the same extended-cycle oral contraceptive category. The relevant commercial comparison was not whether a product used the Seasonique brand name, but whether it used the same active ingredients, strengths, and 84/7 schedule.

Public regulatory records establish generic competition and product approvals. A complete assertion-by-assertion account of every Paragraph IV notice, district-court action, settlement term, or covenant not to sue is not established by the claim text alone.

What Paragraph IV risks did generic manufacturers face?

Before the December 2021 expiration date, a generic applicant submitting an ANDA for a product with the same extended-cycle regimen could have faced a patent challenge based on:

identical 84-day combined dosing;
identical seven-day estrogen-only dosing;
30 μg ethinyl estradiol;
150 μg levonorgestrel;
oral monophasic delivery;
labeling that instructed the same contraceptive schedule.

A Paragraph IV certification would have exposed the applicant to possible patent litigation under 35 U.S.C. § 271(e)(2). If the patent owner sued within the statutory period, FDA approval could have been stayed for up to 30 months, subject to statutory exceptions and court action.

The litigation risk was strongest for a generic label that directly copied the patented regimen. Risk was lower for:

a different cycle length;
a different estrogen-only interval;
a progestin-free interval using no estrogen;
a non-monophasic regimen;
a different progestin;
doses outside the claimed ranges;
a route other than oral where the relevant claim required oral administration.

After expiration, those distinctions no longer provide a patent-based entry advantage against this patent.

What patent litigation and settlement agreements affected the patent?

The central legal issue would have been whether the generic label induced performance of the claimed contraceptive method. Because the claims are method claims, infringement analysis would focus on the product label, prescribing information, patient instructions, and the intended use of the dosage pack.

The patent’s claim structure created several potential litigation positions:

Literal infringement: The generic label expressly instructed an 84/7 regimen with the claimed doses.
Induced infringement: The manufacturer encouraged physicians or patients to perform the claimed method.
Claim differentiation: A product might avoid narrow oral or monophasic claims while still falling within claim 1.
Invalidity: A challenger could argue anticipation or obviousness based on prior extended-cycle contraceptive regimens, known estrogen-progestin combinations, or routine dose selection.
Written description and enablement: A challenger could contest the breadth of the estrogen-equivalent and administration-route language.

No continuing settlement restriction can preserve exclusivity after the patent’s statutory expiration unless independently supported by another enforceable right. A settlement that delayed generic launch only through patent expiration would have no current blocking effect.

How strong was the patent estate for Seasonique?

The estate was commercially meaningful but technically narrow compared with a compound patent.

Strengths

It targeted the exact 84/7 regimen used by the reference product.
Claims 22-24 covered the principal commercial strengths.
The method claims could reach generic labels that copied the branded regimen.
The patent remained in force after FDA approval and after the initial regulatory exclusivity period ended.
Multiple dependent claims created alternative positions around dose, duration, route, and formulation.

Weaknesses

It did not protect ethinyl estradiol or levonorgestrel as chemical entities.
It did not prevent products using different progestins or cycle schedules.
It did not claim a unique tablet composition or manufacturing process.
The 84/7 regimen was exposed to prior-art and obviousness arguments.
Generic applicants could design around individual limitations.
The patent expired in 2021.

The patent was therefore a lifecycle-management asset. Its value came from attaching enforceable method-of-use rights to known contraceptive ingredients rather than from controlling the underlying molecules.

Does U.S. Patent 7,615,545 create biosimilar risk?

No. Biosimilar analysis does not apply to this patent because the covered products are small-molecule hormonal contraceptives, not biologics.

The relevant competitive pathways are:

ANDA approval for therapeutically equivalent generic products;
505(b)(2) applications for products with differences in formulation, route, or regimen;
conventional new-drug applications for materially different contraceptive systems.

A biosimilar applicant would not be the appropriate competitive entrant for Seasonique or its generic equivalents.

What generic launch scenarios existed after expiration?

After December 2021, the principal launch scenarios were:

Scenario	Patent consequence
Exact generic of 30/150 μg active tablets plus 10 μg estrogen tablets	No remaining barrier from U.S. Patent 7,615,545
84-day combined phase with seven-day estrogen-only phase	Same result after expiration
Different estrogen dose within the claimed historical range	Patent expired; no current claim enforcement
Different progestin	Outside many claims, and patent expired
Continuous or alternative extended-cycle regimen	May avoid the historical claims, with no need for avoidance after expiration
Transdermal extended-cycle product	Broad claim 1 historically relevant; no current barrier from this patent
Product using only estrogen during the final phase	Specifically addressed by claims 20-24; patent expired

Commercial launch risk after expiration depends on other patents, FDA approval status, manufacturing capability, supply agreements, and market access. Those issues are separate from the expired patent.

How does the patent compare with competing contraceptive patent strategies?

U.S. Patent 7,615,545 used a regimen-based strategy. Other contraceptive patent strategies typically rely on:

new active ingredients;
long-acting delivery systems;
intrauterine devices;
vaginal rings;
transdermal patches;
controlled-release formulations;
specific manufacturing processes;
treatment or safety indications.

A regimen patent generally has less technical breadth than a compound patent but can be commercially effective when the generic label must reproduce the branded dosing schedule. Its enforceability depends heavily on the instructions for use and on whether the generic product has a materially different regimen.

Key Takeaways

U.S. Patent 7,615,545 covered extended-cycle contraception using estrogen plus levonorgestrel for 81-89 days, followed by low-dose estrogen without progestin for 2-8 days.
Claims 22-24 most closely targeted Seasonique’s 84-day, 30 μg ethinyl estradiol/150 μg levonorgestrel regimen followed by seven days of 10 μg ethinyl estradiol.
The patent covered methods, not the underlying contraceptive molecules.
Oral, monophasic, transdermal, dose-specific, and antidepressant-associated embodiments were included.
Seasonique was approved under NDA 021544 in 2006.
The patent was listed in the Orange Book and could historically support a Paragraph IV challenge and a 30-month regulatory stay.
The patent expired in December 2021 and no longer blocks generic entry.
Biosimilar risk is irrelevant because the products are small-molecule drugs.
Current commercial risk must be assessed against other patents, FDA approvals, manufacturing capacity, and market-specific barriers.

FAQs About U.S. Patent 7,615,545

What product was most directly covered by U.S. Patent 7,615,545?

The closest commercial embodiment was Seasonique, using 30 μg ethinyl estradiol plus 150 μg levonorgestrel for 84 days, followed by seven days of 10 μg ethinyl estradiol.

Could a generic avoid the patent by using a different progestin?

Historically, yes. The principal claims require levonorgestrel at specified daily amounts. A product using a different progestin would not satisfy that limitation, although other patents or regulatory requirements could apply.

Did the patent cover Seasonale or all extended-cycle contraceptives?

No. The claims are directed to specified estrogen-progestin combinations, dose ranges, durations, and routes. They do not automatically cover every extended-cycle contraceptive.

Can a manufacturer still sue over infringement of this patent?

The patent’s term expired in December 2021. It cannot support a new infringement action for conduct occurring after expiration, although historical conduct during the enforceable term could present separate legal issues.

Was the patent a formulation patent or a method-of-use patent?

It was principally a method-of-use patent. The claims protect a contraceptive administration schedule and related dosing parameters rather than a novel chemical composition or manufacturing process.

References

U.S. Patent and Trademark Office. (2009). U.S. Patent No. 7,615,545, Methods of contraception.
U.S. Food and Drug Administration. (2006). Seasonique (levonorgestrel and ethinyl estradiol, and ethinyl estradiol) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug products.
35 U.S.C. §§ 156, 271(e)(2), 271(e)(4), 282.
21 C.F.R. § 314.107.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1453521	⤷ Start Trial	122015000093	Germany	⤷ Start Trial
European Patent Office	1453521	⤷ Start Trial	CA 2016 00016	Denmark	⤷ Start Trial
European Patent Office	1453521	⤷ Start Trial	93156	Luxembourg	⤷ Start Trial
European Patent Office	1453521	⤷ Start Trial	300814	Netherlands	⤷ Start Trial
European Patent Office	1453521	⤷ Start Trial	C20160011 00192	Estonia	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,615,545

Summary for Patent: 7,615,545